| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Provectus Biopharmaceuticals, Inc.
13D/A
PVCT · 74373P108
|
11.6% |
7/22/2026
Event 6/30/2026
|
||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.